S8947-9800-9911-0016A Vitamin D Insufficiency in Determining Prognosis in Patients With Newly Diagnosed Follicular Lymphoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01131221|
Recruitment Status : Completed
First Posted : May 26, 2010
Last Update Posted : May 9, 2014
RATIONALE: Studying samples of serum from patients with cancer in the laboratory may help doctors identify and learn more biomarkers related to cancer. It may also help doctors predict how well patients will respond to treatment.
PURPOSE: This research study is studying vitamin D insufficiency in determining prognosis in patients with newly diagnosed follicular lymphoma.
|Condition or disease||Intervention/treatment|
|Lymphoma||Other: laboratory biomarker analysis|
- To evaluate the role of pre-treatment serum 25(OH)D with regard to progression-free survival and objective response among patients with newly diagnosed follicular lymphoma, within the context of a uniformly treated and evaluated Phase III clinical trial in the modern therapeutic era.
OUTLINE: This is a multicenter study.
Pre-treatment serum samples are analyzed for 25(OH)D levels to determine vitamin D sufficiency or insufficiency.
|Study Type :||Observational|
|Actual Enrollment :||196 participants|
|Official Title:||Vitamin D Insufficiency and Follicular Lymphoma Prognosis|
|Study Start Date :||June 2010|
|Primary Completion Date :||September 2011|
|Study Completion Date :||September 2011|
- Progression-free survival [ Time Frame: retrospective ]
- Objective response (confirmed and unconfirmed complete and partial responses) [ Time Frame: retrospective ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01131221
|Principal Investigator:||Jonathan W. Friedberg, MD||James P. Wilmot Cancer Center|